Analysts fret over absence of placebo comparison in VX-548's...
Analysts fret over absence of placebo comparison in VX-548's trial design, causing uncertainty over its efficacy. The surprise revelation by COO precipitated a drastic dip in shares.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000317f8e75591d45.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment